Physicians who received payment from pharmaceutical companies for meals, talks and travel were more likely to prescribe those companies' drugs for two cancer types, a University of North Carolina Lineberger Comprehensive ...
Apr 9, 2018
0
1
Treatment-free remission seems to be achievable in patients with chronic myeloid leukemia (CML) who have achieved sustained deep molecular response (DMR) after discontinuation of second-line nilotinib therapy. Results from ...
Feb 19, 2018
0
7
Two drugs, already approved for safe use in people, may be able to improve therapy for chronic myeloid leukemia (CML), a blood cancer that affects myeloid cells, according to results from a University of Iowa study in mice.
Sep 25, 2017
0
58
Researchers have uncovered how mutations in a protein network drive several high-risk leukemias, offering new prospects for novel therapies. An existing drug might be repurposed to treat these leukemias, and the new understanding ...
Jun 14, 2017
0
0
In 2002, the FDA approved the drug imatinib as a first-line therapy for adults with chronic myeloid leukemia (CML) caused by the fusion gene BCR-ABL, known as the Philadelphia chromosome. The approval dramatically extended ...
Jun 5, 2017
0
1
Physicians paid by pharmaceutical companies for meals, talks and travel had higher odds of prescribing those companies' drugs to treat two cancer types, a University of North Carolina Lineberger Comprehensive Cancer Center-led ...
Jun 1, 2017
0
1
University of Georgia researchers, with colleagues from the University of Tokyo, have identified a new drug target for the two most common types of myeloid leukemia, including a way to turn back the most aggressive form of ...
May 17, 2017
0
79
Scientists identify two signaling proteins in cancer cells that make them resistant to chemotherapy, and show that blocking the proteins along with chemotherapy eliminate human leukemia in mouse models.
Mar 20, 2017
0
55
Medical advances have offered an increasing number of treatment options to patients with serious and chronic illnesses such as cancer, but these "specialty drugs" often come with a high price tag. A study released today by ...
Mar 17, 2017
0
1
In 2001 the U.S. Food and Drug Administration granted priority review for imatinib mesylate, sold under the name Gleevec, as an oral therapy for patients with chronic myeloid leukemia, or CML.
Mar 9, 2017
0
2
